Quantcast
Last updated on April 19, 2014 at 9:20 EDT

Latest Bacillus anthracis Stories

2012-01-13 11:58:12

Vaccination with the anthrax capsule–a naturally occurring component of the bacterium that causes the disease–protected monkeys from lethal anthrax infection, according to U.S. Army scientists. The study, which appears in the Jan. 20th print edition of the journal VACCINE, represents the first successful use of a non-toxin vaccine to protect monkeys from the disease. Bacillus anthracis, the bacterium that causes anthrax, is recognized as one of the most serious bioterrorism...

2011-10-24 13:41:00

PINE BROOK, N.J., Oct. 24, 2011 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company focused on the development of antibody therapeutics, announced today that it is initiating a new clinical study to further demonstrate the safety of Anthim (ETI-204), the company's anti-toxin in late-stage development for prevention of disease and death from exposure to inhaled anthrax. The company also announced it has successfully manufactured Anthim at commercial scale....

2011-09-08 09:00:00

PINE BROOK, N.J., Sept. 8, 2011 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing biodefense countermeasures, announced today that it has been awarded the first U.S. Government contract to develop an anti-toxin for pre- and post-exposure prophylaxis (PEP) use via intramuscular injection (IM). The five year contract, totaling up to $68.9 million, will support multiple animal efficacy studies as well as human safety studies to further demonstrate...

2011-07-07 00:39:40

An automatic and portable detector that takes just fifteen minutes to analyze a sample suspected of contamination with anthrax is being developed by US researchers. The technology amplifies any anthrax DNA present in the sample and can reveal the presence of just 40 microscopic cells of the deadly bacteria Bacillus anthracis. B. anthracis, commonly known as anthrax, is a potentially lethal microbe that might be used intentionally to infect victims through contamination of food and water...

2011-04-27 13:54:06

It may not be as catchy a combination as "Miss Scarlet in the parlor with a revolver," but "polyester-rayon wipes in the field followed by saline-surfactant extraction and vortexing" is the most efficient solution to an important biological game of "Clue" deduced by researchers at the National Institute of Standards and Technology (NIST). As reported in a recent paper*, the NIST team studied different methods for collecting, extracting and quantifying microbial spores from indoor surfaces to...

2011-04-26 09:05:00

GRONINGEN, The Netherlands, April 26, 2011 /PRNewswire/ -- IQ Therapeutics has completed the dosing of antibody IQNLF in a Phase I clinical trial. A total of 36 healthy volunteers participated in the randomized, placebo controlled, double blind, single dose-escalating study, intended to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of IQNLF. The dosing has been completed successfully and doses up to 7.5 mg/kg have been administered, as per protocol....

2011-02-24 08:04:00

GRONINGEN, The Netherlands, February 24, 2011 /PRNewswire/ -- With the dosing of the first volunteers, Dutch pharmaceutical IQ Therapeutics announced today the initiation of a Phase I clinical trial for IQ-DAA (a combination of two monoclonal human antibodies), a medicine directed against anthrax. IQ-DAA has been developed by IQ Therapeutics for the treatment of inhalation anthrax. Pre-clinical experiments have indicated high efficacy of IQ-DAA, even in advanced stage of disease....

2011-02-08 07:37:00

ANNAPOLIS, Md., Feb. 8, 2011 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that new pharmacokinetic data from the Company's Valortim® anthrax anti-toxin program were presented at the 9th Annual ASM Biodefense and Emerging Diseases Research Meeting, held in Washington, DC, February 6-9, 2011. The data were presented by Dr. Elizabeth Leffel, Director of...

2010-11-17 17:40:33

Studies in mice reveal how bacteria hamper frontline defense cells WHAT: Researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have determined a key mechanism by which Bacillus anthracis bacteria initiate anthrax infection despite being greatly outnumbered by immune system scavenger cells. The finding, made by studying genetically modified mice, adds new detail to the picture of early-stage anthrax infection and supports...

f2c040cd36217b6d5052055c40747a6a1
2010-08-26 12:57:58

An antibacterial enzyme found in human tears and other body fluids could be applied to certain foods for protection against intentional contamination with anthrax, scientists reported today at the 240th National Meeting of the American Chemical Society (ACS). "Data from this study could be used in developing safer foods for human consumption," said Saeed A. Khan, Ph.D. "The data from our study shows that lysozyme application has the potential to eliminate anthrax producing bacteria in...


Latest Bacillus anthracis Reference Libraries

11_ca5cd45b16f3d4936fde0520fef6557b
2011-04-14 14:43:25

Bacillus anthracis is a Gram-positive spore-forming, rod-shaped bacterium, with a width of 1-1.2µm and a length of 3-5µm. It can grow in aerobic or anaerobic conditions. It is the only known bacterium to synthesize a protein capsule and the only pathogenic bacterium to carry its own adenylyl cyclase virulence factor. They form oval spores located centrally in a non-swollen sporangium. These spores are highly resilient and can survive extreme temperatures, low-nutrient environments, and...

More Articles (1 articles) »